EN DE
Watch MEDINEX LIMITED for free: we tell you when fair value or trend changes.
Data-driven stock valuation

MEDINEX LIMITED (OTX) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of MEDINEX LIMITED stock S$0.32, price S$0.22, upside +48.8%, quality 76 out of 100. Rating: undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SG

ML MEDINEX LIMITED logo Thin data Nov 15, 2026

MEDINEX LIMITED

OTX · SG

Cheap (33% below fair value), strong company and rising price: meets all 3 rules.

Get notified free when this changes
Fair value 0.3200 SGD · Undervalued 
Quality 76/100 
Rising price (uptrend) 
Solidly profitable · 17.9% net margin (TTM) 
Low debt 
Generates free cash flow 
Ranks above peers (12/14) 
Even on cautious assumptions the value is 12% above the price (0.2400 SGD). 
Mixed Growth (revenue 5y +2.9 %/yr in SGD) 
7.9% dividend yield · Watch coverage
Wide moat 68/100 · thin data
Thin data 
⚠ Thinly traded⚠ Small free float
Watch MEDINEX LIMITED for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

0.2500 SGD 0.1374 SGD Fair Value 0.3200 SGD Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range 0.1374 SGD – 0.2500 SGD · fair‑value band 0.2400 SGD – 0.4500 SGD · the 0.2150 SGD price screens below the 0.3200 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow MEDINEX in your weekly email

Every Wednesday you see whether MEDINEX is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Medinex Limited, an investment holding company, provides professional support services to medical clinics in Singapore. It operates through four segments: Medical Support Services, Business Support Services, Pharmaceutical Services, and Medical Services.

Show moreShow less

The company engages in the setting up of clinics, facilitating applications for relevant clinic licenses, value added services to healthcare sectors, turnkey solutions, as well as strategic advice to general practitioners and specialists on establishing clinic facilities.

It also provides accounting and tax agent, human resource management, and corporate secretarial services, as well as business support services, such as accounting, tax agent, human resource management, and corporate secretarial services to various sectors, such as food and beverage, retail, education, and beauty.

In addition, the company procures medical and pharmaceutical products to clinics. Further, the company offers diagnostic and x-rays, pre-employment check-ups, vaccination, customized healthcare plans, and health screening services in clinics.

Additionally, it provides advisory services, and business and management consultancy services, call support services, and data protection officer services to its customers; and training services. Medinex Limited was incorporated in 2009 and is headquartered in Singapore.

Stock analysis

MEDINEX LIMITED (OTX) currently trades at 0.2150 SGD, while our model-based Fair Value estimate is 0.3200 SGD, implying the stock looks roughly 33% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of 0.3300 SGD per share, and 18 of the 24 models we run sit above the 0.2150 SGD price.

Bear case: the Asset-Based group reads lowest at 0.0400 SGD, and 6 of the 24 models stay below the price. Data coverage for this calculation is low.

Scenario range: 0.2400 SGD (bear) to 0.4500 SGD (bull), the price of 0.2150 SGD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 76/100 (high quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

MEDINEX LIMITED reported revenue of 12.4M SGD in FY2026 versus 12.0M SGD in FY2022, a compound +0.9%/yr. Reported net income was 2.2M SGD in FY2026, compounding −5.7%/yr from FY2022.

Key figures

Market cap 28.9M SGD (≈ $22.4M) Micro · P/E ratio 10.8 · P/S ratio 1.81 · EPS (TTM) 0.0200 SGD · Dividend yield 7.9% · Net margin 17.9% · Return on equity 13.4% · Return on assets (EBIT) 18.1% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 68 out of 100 (low confidence).

What moves the price

The share trades about 14% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at 49%, OTX screens cheaper than that median.

Fair Value models

Bear 0.2400 SGD Fair Value 0.3200 SGD Bull 0.4500 SGD
Price 0.2150 SGD · Upside +48.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (0.0019 SGD per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 0.2300 SGD 0.3100 SGD 0.4900 SGD 80
Growth DCF 0.2400 SGD 0.3200 SGD 0.4800 SGD 78
Owner Earnings 0.1900 SGD 0.2700 SGD 0.4100 SGD 76
All 24 models by family
DCF Models
FCF DCF 0.2300 SGD 0.3100 SGD 0.4900 SGD 80
Owner Earnings 0.1900 SGD 0.2700 SGD 0.4100 SGD 76
5Y Revenue Exit 0.2100 SGD 0.3000 SGD 0.4300 SGD 73
5Y EBITDA Exit 0.3000 SGD 0.4500 SGD 0.6500 SGD 75
5Y P/E Exit 0.2500 SGD 0.3600 SGD 0.5000 SGD 71
10Y Revenue Exit 0.2100 SGD 0.2800 SGD 0.3500 SGD 68
10Y EBITDA Exit 0.2700 SGD 0.3700 SGD 0.4800 SGD 69
10Y P/E Exit 0.2400 SGD 0.3200 SGD 0.3900 SGD 65
Earnings-Based
Graham-Dodd 0.1100 SGD 0.1400 SGD 0.1500 SGD 67
EPV 0.3100 SGD 0.3600 SGD 0.4000 SGD 74
Dividend Discount
Gordon GGM 0.1600 SGD 0.1800 SGD 0.2100 SGD 69
DDM Multi-Stage 0.1600 SGD 0.2100 SGD 0.2800 SGD 67
Multiples
P/E Multiple 0.2700 SGD 0.3600 SGD 0.4500 SGD 63
P/S Multiple 0.2100 SGD 0.2800 SGD 0.3500 SGD 58
P/B Multiple 0.1500 SGD 0.2000 SGD 0.2500 SGD 55
EV/EBIT 0.4200 SGD 0.5500 SGD 0.6800 SGD 66
EV/EBITDA 0.3900 SGD 0.5100 SGD 0.6300 SGD 67
EV/Revenue 0.2200 SGD 0.3000 SGD 0.3900 SGD 54
Asset-Based
NCAV (Graham) 0.0300 SGD 0.0400 SGD 0.0500 SGD 55
Growth DCF
Growth DCF 0.2400 SGD 0.3200 SGD 0.4800 SGD 78
Rev-Margin DCF 0.2100 SGD 0.3000 SGD 0.4200 SGD 73
Economic Profit
Residual Income 0.1200 SGD 0.1400 SGD 0.1800 SGD 76
ROIC Compounder 0.3100 SGD 0.3700 SGD 0.4300 SGD 72
Growth Earnings
Growth-Adj P/E 0.1900 SGD 0.2700 SGD 0.3600 SGD 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 76/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 67
How much profit the company makes from its sales and capital
Quality Growth 36
Are margins and returns getting better?
Cashflow 77
Do the profits arrive as real cash?
Financial strength 92
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 70
How calm the share price moves, does not count
Price momentum 38
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 35
Distance to the 52-week high, does not count
New shares 72
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 68/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−3.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.9%
Start year 2021 (pandemic)
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+0.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−7.2%
Dividend (yield on the price)7.9%

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−6.2%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Singapore: IMF forecast 2.0% a year to 2030, 1.7% from 2016 to 2025) that is about −8.1% a year for the price.

Watch OTX, get fair value alerts →

Compare MEDINEX LIMITED with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 248 stocks

Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 76 · Top 25%
Fair Value upside +48.8% · Top 25%
Profitability
Return on equity (12 months) 13.4% · Above median
Return on assets 11.4% · Top 25%
Net margin (12 months) 17.9% · Top 25%
Operating margin (12 months) 24.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −2.4% · Bottom 25%
Dividend yield (12 months) 7.9% · Top 25%

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (12 months) 10.8× · Cheapest 25%
P/B 1.36× · Cheaper than median
P/S (12 months) 1.81× · Pricier than median
Price / free cash flow (fiscal year) 8.8× · Cheaper than median
EV/EBITDA 6.3× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)98 · sector 34
FUTURE (revenue growth)0 · sector 33
PAST (return on equity)54 · sector 32
HEALTH (low debt)100 · sector 90
DIVIDEND (yield)100 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $21.86 $45.73 +109% vs OTX
DaVita Inc DVA $174.22 $218.90 +26% vs OTX
Aier Eye Hospital Group 300015 ¥8.99 ¥10.88 +21% vs OTX
HCA Healthcare, Inc HCA $511.78 $547.34 +7% vs OTX
Tenet Healthcare Corporation THC $291.54 $279.20 −4% vs OTX
The Ensign Group ENSG $188.23 $140.09 −26% vs OTX
Encompass Health Corporation EHC $142.11 $94.81 −33% vs OTX
Fresenius SE FRE €53.86 €34.77 −35% vs OTX
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,771 ₹5,234 −40% vs OTX
Dr. Sulaiman Al Habib Medical Services Group 4013 211.40 SAR 109.45 SAR −48% vs OTX

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

MEDINEX LIMITED: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "MEDINEX LIMITED Fair Value". https://www.fairvalue-calculator.com/stock/OTX

Frequently asked questions

Is MEDINEX LIMITED (OTX) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of 0.3200 SGD versus a price of 0.2150 SGD, about +49% upside (undervalued).
What is the fair value of OTX?
Our model-based fair value for MEDINEX LIMITED is 0.3200 SGD (as of Nov 15, 2026), built from audited fundamentals. The current price: 0.2150 SGD.
What is the quality score of OTX?
MEDINEX LIMITED has a Quality Score of 76/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MEDINEX LIMITED (OTX)?
Our model-based price target is the fair value of 0.3200 SGD (as of Nov 15, 2026) from 24 valuation models. Cautious scenario 0.2400 SGD, optimistic scenario 0.4500 SGD. It is a calculation from audited fundamentals, not an analyst target.
What is the MEDINEX LIMITED stock forecast for 2026?
Our models put fair value at 0.3200 SGD, about +49% upside versus a price of 0.2150 SGD (undervalued). Cautious scenario 0.2400 SGD, optimistic scenario 0.4500 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of MEDINEX LIMITED (OTX)?
MEDINEX LIMITED reported trailing-twelve-month revenue of about 12.4M SGD (latest available figure, as of Nov 15, 2026).
Does MEDINEX LIMITED pay a dividend?
MEDINEX LIMITED currently shows a dividend yield of 7.91% relative to its recent price (as of Nov 15, 2026).
How much is the dividend of MEDINEX LIMITED (OTX) and when is the ex-dividend date?
MEDINEX LIMITED pays a dividend of 0.017 SGD per share a year, a dividend yield of 7.9%. The last ex-dividend date was Aug 19, 2026. A dividend has been paid every year since at least 2019. The payout ratio is 85.0% of earnings. Free cash flow covers the dividend 1.11 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into MEDINEX LIMITED (OTX)?
Today's price is already fair in a discounted-cash-flow model if free cash flow at MEDINEX LIMITED shrinks by 6.2 % per year for five years (discount rate 8.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 2.9 % per year. As of Nov 15, 2026.
What discount rate (WACC) does the fair value of OTX use?
Our models discount MEDINEX LIMITED at 8.3 %: a base by market capitalisation (nano), damped by beta 0.17, country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For MEDINEX LIMITED that is -6.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.3 %) and the same formula as our fair value.
How much growth has MEDINEX LIMITED (OTX) delivered so far?
Over the past 5 years revenue at MEDINEX LIMITED grew 2.9 % a year. The price currently implies free-cash-flow growth of -6.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of MEDINEX LIMITED (OTX) growing?
The median revenue growth in the sector is +7.3 % a year. That is the yardstick for the growth priced into MEDINEX LIMITED (-6.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of MEDINEX LIMITED (OTX)?
The free-cash-flow yield on the price is 8.82 %: that much free cash flow MEDINEX LIMITED produces per unit of market value. When it exceeds the discount rate of our models (8.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of MEDINEX LIMITED (OTX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MEDINEX LIMITED it is 0.3200 SGD per share (as of Nov 15, 2026), against a price of 0.2150 SGD. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is MEDINEX LIMITED stock overvalued or undervalued in 2026?
As of Nov 15, 2026, OTX trades below its calculated fair value: price 0.2150 SGD, fair value 0.3200 SGD, a gap of about +49% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OTX?
No. The price is what the market pays today (0.2150 SGD); the fair value is what the company's own numbers justify (0.3200 SGD). For MEDINEX LIMITED the two are 0.1050 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is MEDINEX LIMITED worth?
The market values MEDINEX LIMITED at about 28.9M SGD (market capitalisation, as of Nov 15, 2026). Per share that is 0.2150 SGD; our models calculate a fair value of 0.3200 SGD per share.
What do the bullish and bearish scenarios say about OTX?
Our models span a range for MEDINEX LIMITED: cautious scenario 0.2400 SGD, base 0.3200 SGD, optimistic 0.4500 SGD per share (as of Nov 15, 2026, price 0.2150 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of OTX?
MEDINEX LIMITED trades at a price-to-earnings ratio of 10.8 (as of Nov 15, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 0.3200 SGD is built from several models across several years. Median P/E at fiscal year-end, 6 fiscal years (2021 to 2026), reported earnings: 12.4. Other multiples: P/B 1.4, P/S 1.8, EV/EBITDA 6.3.
How solid is the balance sheet of MEDINEX LIMITED (OTX)?
Balance-sheet figures for MEDINEX LIMITED (as of Nov 15, 2026): return on equity 13.4%. They feed the Quality Score of 76/100, which measures business quality independently of the share price.
How far is OTX from its 52-week high?
MEDINEX LIMITED trades at 0.2150 SGD, about 14% below its 52-week high of 0.2500 SGD and 13% above the low of 0.1900 SGD (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of 0.3200 SGD is for.
Which stocks are comparable to MEDINEX LIMITED?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MEDINEX LIMITED stock attractive at the current price?
The data as of Nov 15, 2026: price 0.2150 SGD, calculated fair value 0.3200 SGD (+49%), Quality Score 76/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OTX calculated?
We run MEDINEX LIMITED through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 0.3200 SGD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. MEDINEX LIMITED currently trades 33% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MEDINEX LIMITED (OTX)?
The closing price on Nov 16, 2026 was 0.2150 SGD. Our model-based fair value is 0.3200 SGD, about +49% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MEDINEX LIMITED right now?
The rarer combination: high quality (76/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (0.2400 SGD). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (0.2400 SGD to 0.4500 SGD) leaves room in how you read the outcome.

Key figures of MEDINEX LIMITED

How large is the market capitalisation of MEDINEX LIMITED (OTX)?
The market capitalisation of MEDINEX LIMITED is 28.9M SGD (≈ $22.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MEDINEX LIMITED (OTX)?
The price-to-sales ratio of MEDINEX LIMITED is 1.81 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of MEDINEX LIMITED (OTX)?
Earnings per share at MEDINEX LIMITED are 0.0200 SGD (price ÷ EPS = P/E 10.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of MEDINEX LIMITED (OTX)?
The dividend yield of MEDINEX LIMITED is 7.9% (payout 85.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of MEDINEX LIMITED (OTX)?
The net margin of MEDINEX LIMITED is 17.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of MEDINEX LIMITED (OTX)?
The return on equity (ROE) of MEDINEX LIMITED is 13.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MEDINEX LIMITED (OTX)?
On an EBIT basis the return on assets of MEDINEX LIMITED is 18.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MEDINEX LIMITED (OTX)?
The operating margin of MEDINEX LIMITED is 24.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MEDINEX LIMITED (OTX)?
Revenue at MEDINEX LIMITED is down 2.4% versus a year earlier (3y avg −1.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at MEDINEX LIMITED (OTX)?
Earnings per share at MEDINEX LIMITED are down 90.8% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch MEDINEX LIMITED in the live analysis

One click puts MEDINEX LIMITED on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.